Related Experiment Video
Updated: Mar 13, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Rapid Initiation of Antiretrovirals in Two Newly Diagnosed HIV-infected Infants
Diana F Clarke1, Inci Yildirim, Ellen R Cooper
1From the *Department of Pediatrics, Boston University School of Medical, Boston, Massachusetts; †Section of Pediatric Infectious Diseases, Boston Medical Center, Boston, Massachusetts; and ‡Division of Infectious Diseases, Department of Pediatrics, Emory University, Atlanta, Georgia.
Insights
Early antiretroviral therapy (ART) for infants with in utero HIV-1 infection shows promise. More research is needed on infant antiretroviral pharmacokinetics, safety, and efficacy for better treatment strategies.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Infants born with in utero Human Immunodeficiency Virus type 1 (HIV-1) infection require prompt treatment.
- Combination antiretroviral therapy (cART) is the standard of care for HIV-1.
- Early initiation of cART is crucial for preventing viral replication and disease progression in neonates.
Observation:
- This study reports the experience with two infants diagnosed with in utero HIV-1 infection.
- Both infants received very early combination antiretroviral therapy (cART) within 4 hours of birth.
Findings:
- The study highlights the administration of cART to infants with in utero HIV-1 infection shortly after birth.
- This case series provides initial insights into the feasibility of extremely early intervention.
Implications:
- Further neonatal studies are essential to understand antiretroviral pharmacokinetics (PKs), safety, and efficacy in this population.
- Developing more potent and tailored antiretroviral regimens for HIV-1-infected infants is critical.
- Optimizing treatment strategies can improve long-term outcomes for vertically infected infants.
Abstract:
We report our experience with 2 infants with in utero HIV-1 infection who began very early combination antiretroviral therapy within 4 hours of birth. Further neonatal studies of antiretroviral pharmacokinetics (PKs), safety, efficacy and treatment strategies are critically needed for the development of more potent regimens for use in HIV-infected infants.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Retroviruses
Size and Structure of Viral Genomes

